课题基金 / 基金详情

PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)

PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)
泰萨菲林钆 IB/II 期重复剂量试验 (PCI-0120)
批准号:
6297775
负责人:
RODNEY H WITHERS
金额:
$0.19万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

RODNEY H WITHERS的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的具体目的是:1)建立适当的 静脉注射格拉司匹林治疗反复发作 放射治疗期间的治疗,确定最大耐受量 每次照射后的剂量和剂量限制毒性 脑转移癌患者的治疗 在最大耐受量下评估另外20名患者 建立安全配置文件。
英文摘要
The specific aims of this study are to: 1) establish an appropriate intravenous dose of Gadolinium Texaphyrin injection for repetitive treatments during radiation therapy, determine the maximum tolerated dose and dose limiting toxicity when each dose is followed by radiation therapy treatment in patient with cancer metastatic to the brain and evaluate an additional 20 patients at the maximum tolerated dose to establish the safety profile.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)
PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)
PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)
PHASE IB/II REPETITIVE DOSE TRIAL OF GADOLINIUM TEXAPHYRIN (PCI-0120)
海外基金